

challenge to overcome this disadvantage and develop a vaccine that has the effect of inducing enhancement of Th1 cellular immunity that causes ADCC in addition to the neutralizing function through humoral immunity. In particular, in the case of inactivated vaccines, it is common to use various adjuvants distinct from aluminum hydroxide gels to strengthen immune function. However, this poses a challenge for commercialization due to the need for expensive adjuvants. Therefore, the development of an effective inactivated Zika vaccine without using additional inactivating agents or adjuvant still remains a challenge.

[0004] [Prior Art Document]

[0005] [Patent Document]

[0006] (Patent Document 0001) 1. Korea Patent Application Publication No. 10-2019-0127605 (published on November 13, 2019)

SUMMARY

[0006a] In one aspect, provided herein is a vaccine composition comprising Zika virus inactivated by epigallocatechin-3-gallate (EGCG) as an active ingredient.

DISCLOSURE OF THE INVENTION

TECHNICAL PROBLEM

[0007] An object of the present invention is to provide a vaccine composition including Zika virus inactivated by epigallocatechin-3-gallate (EGCG) as an active ingredient.

TECHNICAL SOLUTION

[0008] In order to achieve the above object, the present invention provides a vaccine composition including Zika virus

inactivated by epigallocatechin-3-gallate (EGCG) as an active ingredient.

ADVANTAGEOUS EFFECTS

[0009] According to the present invention, the Zika virus